Sugi Predict

Sugi Predict / Targets / ALOX5AP

ALOX5AP

Arachidonate 5-lipoxygenase-activating protein · P20292 · ALOX5AP on Sugi Atlas →

87,644 patent compounds predicted against ALOX5AP, 29,993 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL9535 SCHEMBL9535 1.00 20/20
Fiboflapon Fiboflapon (SCHEMBL11820) 1.00 20/20
SCHEMBL166785 SCHEMBL166785 1.00 20/20
SCHEMBL167794 SCHEMBL167794 1.00 20/20
SCHEMBL167864 SCHEMBL167864 1.00 20/20
SCHEMBL168681 SCHEMBL168681 1.00 20/20
SCHEMBL168991 SCHEMBL168991 1.00 20/20
SCHEMBL169013 SCHEMBL169013 1.00 20/20
SCHEMBL169228 SCHEMBL169228 1.00 20/20
SCHEMBL169386 SCHEMBL169386 1.00 20/20
SCHEMBL169407 SCHEMBL169407 1.00 20/20
SCHEMBL169564 SCHEMBL169564 1.00 20/20
SCHEMBL169605 SCHEMBL169605 1.00 20/20
SCHEMBL169607 SCHEMBL169607 1.00 20/20
SCHEMBL169704 SCHEMBL169704 1.00 20/20
SCHEMBL169843 SCHEMBL169843 1.00 20/20
SCHEMBL169920 SCHEMBL169920 1.00 20/20
SCHEMBL169943 SCHEMBL169943 1.00 20/20
SCHEMBL169961 SCHEMBL169961 1.00 20/20
SCHEMBL169982 SCHEMBL169982 1.00 20/20

Clinical trials — most relevant to ALOX5AP by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of Ticagrelor on 15-Epi-Lipoxin A4 and Inflammation PHASE4WITHDRAWN
Predicting Response to Standardized Pediatric Colitis Therapy PHASE4COMPLETED
Atorvastatin, Aspirin, Oxidative Stress, Coagulation and Platelet Activation Indexes PHASE4UNKNOWN
Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids PHASE2/PHASE3COMPLETED
Wheeze and Intermittent Treatment PHASE3COMPLETED
Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM PHASE3COMPLETED
Montelukast in Parkinson Disease PHASE2/PHASE3RECRUITING
Montelukast for Early Life Wheezing PHASE2/PHASE3COMPLETED
Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA PHASE2/PHASE3COMPLETED
Aspirin for Uncontrolled Asthma PHASE3COMPLETED
GSK2190915 Neutrophilic Asthma Study PHASE2COMPLETED
GSK2190915A - Bioavailability Study PHASE1COMPLETED
A Repeat Dose Study to Investigate the Interaction of GSK2190915 on the Pharmacokinetics of Rosuvastatin PHASE1COMPLETED
A Single Dose Study to Assess the Regional Absorption and Bioavailability of 100mg GSK2190915A PHASE1COMPLETED
Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide PHASE1COMPLETED
Trial of Zileuton CR in Children and Adults With Sickle Cell Disease PHASE1COMPLETED
Fish Oil to Prevent Asthma Exacerbations in Patients With ALOX5 Polymorphisms nanCOMPLETED
Heart & Health Study nanCOMPLETED
The Severe Asthma Research Program III-Boston Clinical Site nanCOMPLETED
Fatty Acid Regulation of Platelet Function in Diabetes nanCOMPLETED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish) nanUNKNOWN
Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A nanACTIVE_NOT_RECRUITING
Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B nanCOMPLETED
Study of the Arachidonate 5-Lipoxygenase Enzyme in Affecting the Risk for Coronary Heart Disease nanCOMPLETED
Eicosanoid Lipids by Airway Cells During Infection With Human Rhinoviruses nanCOMPLETED
Leukotrienes Pathway in Chinese Children With Sleep-disordered Breathing nanUNKNOWN
Investigation of Lipoxin A4, Annexin A1 and Interleukin-1 Beta Levels in Individuals With Periodontitis. nanCOMPLETED
Eicosanoids in Human Heart Failure nanUNKNOWN
Oxidative Lipidomic Biomarkers During Mechanical Ventilation in Critically Ill Patients (OXY-BAL). nanRECRUITING
PLatelets Acetyl-CoA Carboxylase Phosphorylation State in SEPtic Shock nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ALOX5AP binder may also engage these)

ProteinNameSimilarity
P30355 — 1.000 P30355 →
P20291 — 1.000 P20291 →
Q148F2 — 1.000 Q148F2 →
P30358 — 1.000 P30358 →
Q2PG08 — 1.000 Q2PG08 →
P30356 — 0.999 P30356 →
P30354 — 0.999 P30354 →
P30357 — 0.998 P30357 →
P30353 — 0.993 P30353 →
Q9GKZ4 — 0.933 Q9GKZ4 →
Q8W4Y5 — 0.933 Q8W4Y5 →
Q29RU6 — 0.932 Q29RU6 →
Q5VWC8 — 0.932 Q5VWC8 →
Q6DED0 — 0.931 Q6DED0 →
Q9LDF2 — 0.930 Q9LDF2 →
TRAM1 Translocating chain-associated membrane protein 1 0.929 landscape →
Q9DBN1 — 0.929 Q9DBN1 →
Q91WB2 — 0.928 Q91WB2 →
Q6YWS8 — 0.928 Q6YWS8 →
Q19KA1 — 0.928 Q19KA1 →
Q9QXY7 — 0.928 Q9QXY7 →
Q0III2 — 0.928 Q0III2 →
Q8TCT6 — 0.928 Q8TCT6 →
O19133 — 0.928 O19133 →
Q9CUS9 — 0.927 Q9CUS9 →
Q1PET6 — 0.927 Q1PET6 →
Q5R7Z3 — 0.926 Q5R7Z3 →
A6ZIQ8 — 0.926 A6ZIQ8 →
Q5FVJ3 — 0.926 Q5FVJ3 →
Q6EUN0 — 0.925 Q6EUN0 →